+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Metabolic Disorder Drug"

Hyperinsulinemia - Pipeline Review, H1 2020 - Product Thumbnail Image

Hyperinsulinemia - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 77 Pages
  • Global
From
From
From
Diabetic Retinopathy Global Clinical Trials Review, H2, 2020 - Product Thumbnail Image

Diabetic Retinopathy Global Clinical Trials Review, H2, 2020

  • Clinical Trials
  • August 2020
  • 331 Pages
  • Global
From
From
From
From
From
From
From
From
Loading Indicator

The Metabolic Disorder Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. It includes drugs used to treat metabolic disorders such as diabetes, obesity, and hyperlipidemia. These drugs are used to regulate the body's metabolism, which is the process of converting food into energy. Common drugs used to treat metabolic disorders include insulin, sulfonylureas, biguanides, thiazolidinediones, and GLP-1 agonists. These drugs are used to control blood sugar levels, reduce cholesterol, and promote weight loss. The Metabolic Disorder Drug market is highly competitive, with many companies offering a variety of drugs to treat metabolic disorders. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. Other companies in the market include Boehringer Ingelheim, Takeda, and Pfizer. Show Less Read more